Can Immunotherapy Cause Significant Lymph Node Swelling in Melanoma?
Yes, immunotherapy for melanoma can cause significant lymph node swelling, specifically a phenomenon called "sarcoid-like lymphadenopathy" or granulomatous lymphadenitis, which appears in approximately 10% of patients and paradoxically may indicate treatment response rather than disease progression.
Understanding This Immune-Related Adverse Event
Lymph node swelling during immunotherapy represents a recognized immune-related adverse event that requires careful clinical interpretation:
Key Clinical Patterns
The granulomatous reaction typically manifests as:
- Mediastinal and hilar lymphadenopathy appearing approximately 6 months after immunotherapy initiation 1
- "Sarcoid-like lymphadenopathy" visible on PET/CT imaging 2
- Can mimic disease recurrence or progression both clinically and radiographically 1
Critical Diagnostic Distinction
This is a crucial clinical pitfall: The lymph node enlargement may appear identical to metastatic disease on imaging, but biopsy reveals benign granulomatous inflammation rather than tumor cells 1. All patients who developed this sarcoid-like pattern in one study showed disease control, suggesting this may be a favorable prognostic sign 2.
Clinical Management Algorithm
When encountering new lymphadenopathy during immunotherapy:
- Consider timing: Typically occurs around 6 months into treatment 1
- Evaluate disease response: If other disease sites show favorable response, suspect immune-related lymphadenopathy rather than progression 1
- Obtain tissue diagnosis: Biopsy is essential to differentiate granulomatous reaction from metastatic disease 1
- Continue immunotherapy: If biopsy confirms granulomatous reaction, immunotherapy should be continued as this represents an immune-related adverse event, not treatment failure 1
Prognostic Implications
The presence of this lymphadenopathy may actually be favorable: In the study evaluating ipilimumab-treated patients, all patients (100%) who developed sarcoid-like lymphadenopathy achieved disease control, with some achieving complete or near-complete responses 2, 1. This suggests the lymph node changes reflect robust immune activation rather than treatment failure.
Important Caveats
- This phenomenon is distinct from baseline lymph node involvement by melanoma
- Not all lymph node enlargement during immunotherapy is benign—tissue diagnosis is mandatory to avoid premature treatment discontinuation
- The 10% incidence means most patients will not develop this finding 2
- Awareness of this adverse event is crucial to prevent inappropriate treatment cessation in responding patients 1
The ESMO guidelines on immunotherapy toxicity management 3 emphasize that immune-related adverse events can affect multiple organ systems, and lymphoid tissue changes represent one manifestation of immune activation during checkpoint inhibitor therapy.